Barinthus Biotherapeutics plc held its 2026 Annual General Meeting on July 2, 2026, where shareholders approved all submitted ordinary resolutions, including the re-election of directors Karen T. Dawes and Anne M. Phillips and the re-appointment of PricewaterhouseCoopers LLP. Additionally, the company received an extension notice from Nasdaq on June 30, 2026, granting an additional 180 days, until December 28, 2026, to regain compliance with the minimum $1.00 bid price requirement. Consequently, the company's American Depositary Shares were transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective July 2, 2026. The company is considering a reverse stock split to resolve the deficiency. Barinthus Biotherapeutics plc is a biotechnology company.